Clinical Trials Related to Urothelial Carcinoma

Related studies linked through entity extraction aliases.

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Status: TERMINATED
Phase: PHASE2

Prospective Multicentric Evaluation of a Bladder Preservation Strategy

Status: TERMINATED
Phase: PHASE2

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Status: WITHDRAWN
Phase: PHASE2

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Status: TERMINATED
Phase: PHASE2

Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan

Status: UNKNOWN
Phase: N/A

Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma

Status: UNKNOWN
Phase: N/A

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Status: COMPLETED
Phase: PHASE2

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

Status: TERMINATED
Phase: PHASE1

Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

Status: COMPLETED
Phase: PHASE1